Following ASCO preview flop, Syndax bets on new combo deal with Nektar
San Fran’s I/O darling Nektar Therapeutics $NKTR is handing off access to its popular cancer candidate NKTR-214 to see how the therapy fairs when paired with Syndax’s struggling drug entinostat.
The duo inked a collaboration and licensing deal that gives Syndax $SNDX the right to run a combo study testing the drugs against metastatic melanoma in patients who have previously progressed when on an anti-PD-1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.